BUMEX Drug Patent Profile

When do Bumex patents expire, and what generic alternatives are available?

Bumex is a drug marketed by Validus Pharms and is included in two NDAs.

The generic ingredient in BUMEX is bumetanide. There are six drug master file entries for this compound. Thirty-nine suppliers are listed for this compound. Additional details are available on the bumetanide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Bumex

A generic version of BUMEX was approved as bumetanide by SAGENT on January 27^th, 1995.

Summary for BUMEX

US Patents:	0
Applicants:	1
NDAs:	2

US Patents and Regulatory Information for BUMEX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Validus Pharms	BUMEX	bumetanide	INJECTABLE;INJECTION	018226-001	Feb 28, 1983		DISCN	Yes	No
Validus Pharms	BUMEX	bumetanide	TABLET;ORAL	018225-003	Jun 14, 1985	AB	RX	Yes	No
Validus Pharms	BUMEX	bumetanide	TABLET;ORAL	018225-002	Feb 28, 1983	AB	RX	Yes	No

International Patents for BUMEX

See the table below for patents covering BUMEX around the world.

Country	Patent Number	Title	Estimated Expiration
France	2027043
Israel	33526	SULPHAMYL-BENZOIC ACID DERIVATIVES,THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
Germany	1966878	3-BUTYLAMINO-4-PHENOXY-5-SULFAMYLBENZOESAEURE UND DEREN DERIVATE, VERFAHREN ZU IHRER HERSTELLUNG UND DIESE ENTHALTENDE MITTEL

BUMEX Market Analysis and Financial Projection

Last updated: February 3, 2026

What Is the Investment Landscape for BUMEX?

BUMEX (bumetanide) is a loop diuretic primarily prescribed for edema associated with congestive heart failure, liver cirrhosis, and renal disease. While it has established clinical use, its investment potential depends on regulatory status, competitive landscape, and unmet medical needs.

Current market valuation for bumetanide is modest compared to high-profile therapeutics but has niche demand. The drug’s generic status minimizes patent risk, indicating limited exclusivity. The key to investment potential lies in its repositioning for additional indications, novel formulations, or combination therapies.

What Are the Fundamentals of BUMEX as an Investment?

Market Size and Growth

The global diuretics market is valued at approximately USD 5 billion in 2022, with an annual growth rate of about 3% (Grand View Research). Bumetanide accounts for a small fraction of this market, estimated at under USD 300 million. Growth drivers include rising prevalence of heart failure and hepatic conditions.

Clinical Development and Regulatory Status

BUMEX has been marketed for decades with generic status. No recent approvals for new indications have been achieved by the original manufacturers. Some research explores off-label uses, such as neuroprotective effects in neurological disorders, but these remain investigational.

Patent and Exclusivity Considerations

The drug's patent positions have long expired. Its generics face competition worldwide, reducing pricing power. Patent opportunities now are limited to formulation patents or new delivery methods.

Competitive Landscape

Generic diuretics such as furosemide and torsemide dominate the market, with bumetanide often regarded as a second-line option. No current major pharmaceutical companies have substantial market exclusivity focused on bumetanide. Potential investment would require differentiation strategies or niche repositioning.

Unmet Medical Needs and Off-Label Opportunities

Research suggests possible roles of bumetanide in neuropsychiatric and neurological disorders, such as autism spectrum disorder and epileptic syndromes. However, clinical evidence remains limited. Off-label use is not authorized without substantial data; thus, risk and regulatory hurdles are high.

Investment Risks and Opportunities

Key risks include:

• Limited patent protection
• Market competition from generics
• Regulatory barriers for new indications
• Limited pipeline for novel formulations

Opportunities could stem from intellectual property on formulations, advocacy for expanded indications, or partnerships with academic institutions exploring new uses.

What Is the Regulatory Outlook and Market Potential?

Regulatory Pathway: Repositioning bumetanide for new therapeutic indications would require phase I–III clinical trials, with an average timeline of 7–10 years and costs exceeding USD 100 million per indication.

Market Penetration: Even with successful approval, the niche nature of potential additional indications means the overall market impact might be limited unless breakthroughs occur.

Pricing and Reimbursement: As a generic, bumetanide's pricing is low, but new formulations or delivery methods could command premiums and improve margins.

What Strategic Approaches Could Enhance Investment Value?

• Formulation Innovation: Developing sustained-release or injectable forms to open new administration routes.
• Combination Therapies: Combining bumetanide with other drugs to target complex syndromes.
• Indication Expansion: Conducting trials to explore neuroprotective or off-label uses with promising preliminary data.
• Patent Strategy: Securing formulation patents or delivery device patents.

Key Takeaways

Bumetanide's current investment prospects are limited by patent expiry, generic competition, and small market share. Opportunities exist in niche indications and formulation enhancements, but these require significant R&D investment and lengthy regulatory processes. The drug remains more of a low-cost, high-volume therapeutic with limited high-margin upside unless used as a platform for innovation.

FAQs

1. Is BUMEX a high-profit investment?
No, due to its generic status and limited indication exclusivity, profit margins are constrained. Investment profitability hinges on niche repositioning or new formulations.

2. Are there any approved new indications for bumetanide?
No. Current approvals are limited to its traditional diuretic use.

3. What is the main competitive advantage for investors?
Formulation innovation or developing new therapeutic indications could create differentiation and potential exclusivity.

4. What hurdles must be overcome for bumetanide repositioning?
Regulatory approval for new indications and securing funding for costly clinical trials.

5. How does market competition influence bumetanide’s value?
Presence of low-cost generics diminishes pricing power, limiting revenue unless differentiation or niche markets are targeted.

---

References:

1. Grand View Research. Diuretics Market Size, Share & Trends Analysis. 2022.